Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

DNA-Ligands as Therapeutics for C9orf72 Repeat Expansion Diseases

EF 2025-26

Résumé
Expansions of gene-specific tandem DNA repeats cause nearly 100 neurodegenerative diseases, including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Expansions of (CAG)n repeats in the Huntingtin gene, HTT, cause HD, while expansions of (GGGGCC)n repeats in the C9orf72 gene is the major cause of ALS and FTD. Ongoing somatic repeat expansions in patient brains drive disease, such that arresting or reversing these could be therapeutically beneficial. Somatic expansions involve unusual DNA structures formed within the GGGGCC and CAG repeats. These unusual DNA structures are processed by DNA repair proteins to larger expanded repeats. The Pearson lab has identified CAG structure specific ligands that allow the bound CAG structures to be processed to contractions rather than expansions. My project aims to identify GGGGCC DNA structure specific ligands that may induce contractions of ALS/FTD-causing C9orf72 repeat expansions. GGGGCC repeats form unusual quadruplex DNA structures that are processed to expansions. The Pearson Lab identified naphthyridine carbamate dimer (NCD) and N-3-aminopropyl-1,3-bis (2-amino-1,8-naphthyridine-7-yl) propane-2-carboxamide (ANP77), which bind to GGGGCC quadruplexes to alter their processing by FAN1, a nuclease implicated in suppressing expansions in repeat diseases. I will determine the ability of these molecules to modulate repeat instability in the C9orf72 mouse model, by delivering multiple doses to brains of 4-month-old C9orf72 mice and comparing repeat instability to mock-treated control C9orf72 mice. Despite decades of effort, ALS/FTD drug trials have failed. My project aims to identify molecules with potential to be disease-modifying therapies for the most common cause of ALS and FTD.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572542
Name
Singh Isha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
DNA-Ligands as Therapeutics for C9orf72 Repeat Expansion Diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Amyotrophic Lateral Sclerosis (Als); Anp77; C9orf72; Fan1 Nuclease; Frontotemporal Dementia (Ftd); Ncd; Somatic Expansions
Abstract
Expansions of gene-specific tandem DNA repeats cause nearly 100 neurodegenerative diseases, including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Expansions of (CAG)n repeats in the Huntingtin gene, HTT, cause HD, while expansions of (GGGGCC)n repeats in the C9orf72 gene is the major cause of ALS and FTD. Ongoing somatic repeat expansions in patient brains drive disease, such that arresting or reversing these could be therapeutically beneficial. Somatic expansions involve unusual DNA structures formed within the GGGGCC and CAG repeats. These unusual DNA structures are processed by DNA repair proteins to larger expanded repeats. The Pearson lab has identified CAG structure specific ligands that allow the bound CAG structures to be processed to contractions rather than expansions. My project aims to identify GGGGCC DNA structure specific ligands that may induce contractions of ALS/FTD-causing C9orf72 repeat expansions. GGGGCC repeats form unusual quadruplex DNA structures that are processed to expansions. The Pearson Lab identified naphthyridine carbamate dimer (NCD) and N-3-aminopropyl-1,3-bis (2-amino-1,8-naphthyridine-7-yl) propane-2-carboxamide (ANP77), which bind to GGGGCC quadruplexes to alter their processing by FAN1, a nuclease implicated in suppressing expansions in repeat diseases. I will determine the ability of these molecules to modulate repeat instability in the C9orf72 mouse model, by delivering multiple doses to brains of 4-month-old C9orf72 mice and comparing repeat instability to mock-treated control C9orf72 mice. Despite decades of effort, ALS/FTD drug trials have failed. My project aims to identify molecules with potential to be disease-modifying therapies for the most common cause of ALS and FTD.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Singh, Isha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~